-
Biogen Analysts Brace For Favorable Aducanumab Adcom Verdict
Thursday, November 5, 2020 - 3:00pm | 543Read More...Biogen Inc (NASDAQ: BIIB) shares saw a nice 40% bump Wednesday following the release of FDA briefing document prepared for Friday's Adcom meeting to discuss aducanumab BLA. Morgan Stanley analyst Matthew Harrison maintained an Overweight rating and $357 price target. BofA Securities...
-
Biogen's Best-In-Class R&D Earn Makes It A Buy
Tuesday, October 17, 2017 - 11:35am | 363Read More...Analysts at Stifel turned bullish on Biogen Inc (NASDAQ: BIIB) for four key reasons. The firm's Thomas Shrader upgrades Biogen's stock from Hold to Buy with a price target boosted from $300 to $415. First, there have been no news reports on the "gigantic" aducanumab phase 3 trial, which started in...
-
Momenta Pharma Could Face Pressure Following Approval Of Mylan's Generic Copaxone
Thursday, October 5, 2017 - 8:58am | 435Read More...The U.S. Food and Drug Administration's approval of Mylan N.V. (NASDAQ: MYL)'s generic version of Copaxone for the treatment of relapsing multiple sclerosis should be seen as a "clear negative" for Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)'s Glatopa franchise, analysts at Baird said. The firm's...
-
Stifel Lays Out 3 Scenarios For Medivation Takeover
Monday, May 2, 2016 - 2:49pm | 318Read More...Stifel analyst Thomas Shrader laid out three scenarios for Medivation Inc (NASDAQ: MDVN) takeover after the biopharma company rejected Sanofi SA (ADR) (NYSE: SNY)'s $52.50 acquisition bid. Shrader raised his target price on the stock by $14 to $66, which is also his minimum takeover price for...
-
Vitae's Drug Potential 'Significant,' Stifel Upgrades To Buy
Thursday, March 17, 2016 - 9:53am | 246Read More...Stifel’s Thomas Shrader upgraded the rating for Vitae Pharmaceuticals Inc (NASDAQ: VTAE) from Hold to Buy, with a price target of $15, after the company reported top line data for VTP-43742 indicating significant potential. Vitae reported that statistically significant PASI reductions...
-
Molecular Biology Firm Intrexon Is Close To Generating 'Significant' Product Revenue
Monday, September 21, 2015 - 2:02pm | 350Read More...In a report issued Monday, Stifel initiated coverage of Intrexon Corp (NYSE: XON) with a Buy rating. Analysts Thomas Shrader and Alex Schwartz set a price target of $69.00 for the stock. Shares of the mid-cap company are down more than 5 percent on Monday's trading. According to the...
-
Stifel, JMP Securities Discuss What To Expect From AAIC Conference
Monday, July 20, 2015 - 8:30am | 464Read More...In a report published Monday, JMP Securities analyst Michael King discussed the potential upside for the biotech sector ahead of the upcoming Alzheimer's Association International Conference (AAIC) that will take place July 18 through July 23 in Washington, D.C. King noted various media...
-
Stifel Downgrades Biogen Amid Concerns Of Lack Of Upcoming Data, Overvaluation
Monday, March 23, 2015 - 8:46am | 155Read More...Stifel issued a report on Monday downgrading Biogen Idec Inc (NASDAQ: BIIB) from Buy to Hold as definitive clinical data for its main drug BIIB037 is years away. Stifel has a $451 price target on Biogen shares. Analyst Thomas Shrader wrote, "...as we enter a somewhat quiet time for the BIIB037 and...
-
Stifel Says Acorda Therapeutics Decline Is 'A Buying Opportunity'
Wednesday, February 11, 2015 - 6:42pm | 252Read More...Stifel commented on Acorda Therapeutics Inc (NASDAQ: ACOR) Wednesday after the stock fell from approximately $40 to $36 Tuesday afternoon. Analyst Thomas Shrader noted that the stock may have been impacted by a legal attack on a patent covering Ampyra, and the CEO telling a crowd at “...
